Doctor talking to a male patient in an office setting

HIV Suppression Management

Management of HIV-1 Treatment Regimens When There Is Virologic Suppression

Suppression management refers to modification to antiretroviral (ARV) treatment for patients with viral suppression. Advances in ARV therapy offer improved durability and tolerability

supporting image

Reasons for modification can include:

  • Side effects
  • Adverse events
  • Regimen simplification
  • Drug-drug interactions
  • Concern for long-term toxicities
  • Regimen intolerance
  • Optimization of antiretroviral (ARV) treatment in pregnancy

Labcorp offers two assays to support 
suppression management.

GenoSure Archive®

GenoSure Archive® was designed to provide HIV-1 anti-retroviral (ARV) resistance data when a patient’s viral load is suppressed or too low for standard resistance testing.  The assay interrogates the viral archive in  peripheral blood mononuclear cells (PBMCs) using next-generation sequencing (NGS) to identify archived mutations and to then assign susceptibility calls of sensitive, resistant and resistance possible based on those mutations.  Drug classes evaluated by GenoSure Archive® include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (INIs) and protease inhibitors (PIs).

Trofile® DNA

Trofile® DNA utilizes cell-associated viral DNA to determine tropism in patients with viral loads less than 1000 copies/mL. The assay incorporates the single cycle recombinant phenotype of Trofile® to cell-associated viral DNA. Trofile® DNA is a patient selection assay which identifies patients appropriate for use of a CCR5 antagonist for HIV-1 treatment when the viral load is < 1000 copies/mL.